Ireland's national drugs budget is mainly spent on obesity, cancer, rare diseases, and diabetes — with some drugs such as Saxenda, patients seeking reimbursement must apply individually ...

This continuing education course details the role of GLP-1 injectables in managing chronic conditions and overweight/obesity, ...

Medications like Ozempic and Zepbound are reducing the risk of death for people with certain conditions. Can they do the same ...

In France, Wegovy is prescribed as a second-line treatment for obesity, not for people with a lower body mass index (BMI) or ...

France's ANSM fines Novo Nordisk and Eli Lilly over illegal obesity drug advertising, raising concerns over public health ...

Agency proposal would exclude semaglutide, tirzepatide, and liraglutide from 503B bulks li ...

GLP-1 receptor agonists may not raise the risk for diabetic ketoacidosis or pancreatitis among adults with type 1 diabetes, ...

People who stop taking GLP-1 drugs like Ozempic, Wegovy and others for weight loss are projected to regain the lost weight ...

As competition mounts in the red-hot market for weight loss drugs, France’s medicines regulator fined Novo Nordisk ...

Millions of people use GLP-1 medicines.

Research suggests that people who stop taking GLP-1 medications such as Ozempic, Wegovy and similar products are likely to ...

St Andrews researchers carried out the largest review of its kind and found no increased risk in birth defects from weight-loss drugs such as Ozempic, Wegovy and Mounjaro ...